Research Guide | Triple Agonist Peptide
What Is Retatrutide? — Triple Receptor Agonist Research Guide
Retatrutide (LY3437943) is a synthetic peptide studied as a GLP-1/GIP/glucagon triple receptor agonist — the first compound in its class to simultaneously activate all three metabolic receptor targets. This guide covers its mechanism, receptor pharmacology, clinical research data, and sourcing for laboratory use.
What Is Retatrutide?
Retatrutide (development code LY3437943, also referred to as GLP-3 Reta in some research shorthand) is a synthetic peptide developed by Eli Lilly as an investigational compound. It is classified as a triple receptor agonist because it simultaneously activates three distinct G protein-coupled receptors central to metabolic regulation: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This triple-receptor activation profile is what distinguishes retatrutide from all other current and investigational metabolic peptides. Semaglutide activates only GLP-1R. Tirzepatide activates GLP-1R and GIPR (dual agonist). Retatrutide adds GCGR to this dual foundation, creating a mechanistically unique compound that has generated significant interest in metabolic and hepatic research.
Retatrutide Mechanism of Action
GLP-1 Receptor (GLP-1R) — Primary Incretin Pathway
GLP-1R activation is the shared mechanism of the entire incretin peptide class. GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells in response to nutrient intake. At the pancreatic beta cell, GLP-1R activation stimulates glucose-dependent insulin secretion via cAMP-mediated pathways. At the alpha cell, it suppresses inappropriate glucagon secretion. Centrally, GLP-1R activation in the hypothalamus and vagal afferents produces satiety signaling. Gastric emptying is slowed, reducing postprandial glucose excursions.
GIP Receptor (GIPR) — Amplification and Tolerability
GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. GIPR activation amplifies insulin secretion, signals in adipose tissue to enhance fatty acid storage regulation, and appears to modulate nausea responses to GLP-1R agonism. Adding GIPR activation (as tirzepatide did over semaglutide) was associated with enhanced metabolic efficacy in comparative trials. Retatrutide includes this dual incretin activation as its baseline.
Glucagon Receptor (GCGR) — The Triple Agonist Differentiator
GCGR activation is what makes retatrutide mechanistically unique. Glucagon receptor activation normally increases hepatic glucose output and drives lipolysis in adipose tissue. In isolation, this would be counterproductive for metabolic research involving glucose management. However, in the context of simultaneous GLP-1R and GIPR agonism, the insulinotropic counterbalancing effect of both incretin receptors preserves glycemic stability while the thermogenic, lipolytic, and hepatic effects of GCGR activation are maintained. The result is a net increase in energy expenditure and enhanced lipid mobilization on top of the incretin effects.
Key insight: Retatrutide adds GCGR agonism to the GLP-1R and GIPR receptor pair. That third receptor arm is the mechanistic variable isolated in triple- versus dual- and mono-agonist comparison studies.
Retatrutide vs Semaglutide vs Tirzepatide
| Compound | Class | Receptors |
|---|---|---|
| Semaglutide | GLP-1 mono-agonist | GLP-1R only |
| Tirzepatide | GLP-1/GIP dual agonist | GLP-1R + GIPR |
| Retatrutide | Triple agonist | GLP-1R + GIPR + GCGR |
Retatrutide in Laboratory Research
As a research-use-only compound, retatrutide is used in preclinical and in vitro laboratory settings to study:
- Multi-receptor metabolic pathway co-activation — examining how simultaneous GLP-1R, GIPR, and GCGR engagement differs from dual or single receptor activation
- Hepatic lipid-handling pathways — examining the GCGR contribution in controlled hepatic signaling models
- Comparative incretin pharmacology — using retatrutide alongside tirzepatide and semaglutide to isolate receptor-specific contributions
- Energy-expenditure signaling — studying GCGR-mediated pathways within a controlled incretin context
- Adipocyte lipid-mobilization signaling — examining GCGR effects in laboratory adipocyte models
Sourcing Retatrutide for Research
OligoPoly Laboratories supplies retatrutide as a lyophilized research peptide with a theoretical MW of 4,731.33 g/mol. Testing documentation is provided only when available for the specific released lot. A batch-specific Certificate of Analysis is available via our online COA verification system. Ships from Houston, TX with 1–3 business day processing.
Related Research Resources
- Retatrutide vs Tirzepatide — Side-by-side receptor and efficacy comparison
- Retatrutide vs Semaglutide — Triple agonist vs selective GLP-1 comparator
- Triple Agonist Peptide Guide — Complete guide to the triple agonist research class
- GLP-1 Receptor Mechanism — In-depth GLP-1R pharmacology
- Metabolic Peptide Comparison Hub — Full metabolic research peptide index
Research Use Only: All compounds referenced on this page are strictly for laboratory and in vitro research purposes only. Not intended for human use, veterinary use, or diagnostic/treatment purposes. OligoPoly Laboratories sells research-grade peptides exclusively to qualified researchers.
Single-Compound Research Materials Referenced in This Guide
For Research Use Only · Third-Party Tested · COA Documentation · Ships from Houston TX